How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AC

NASDAQ:ACRS
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AC

Aclaris Therapeutics IncNASDAQ ACRS Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is ACRS undervalued compared to its fair value?

The fair value of ACRS stock is hidden USD. Relative to the market price of 1.31 USD Aclaris Therapeutics Inc is hidden.

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology an...[More about valuation]

Aclaris Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.095 $B

Price:

1.31 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.238

FINANCIALS

Aclaris Therapeutics financial for reporting period

Income Statement

0.0024 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.019 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.017 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0024 B 100%
0.0006 B 23%
-0.019 B -789%
-0.017 B -706%

Balance Sheet

0.17 B
0.14 B

Financial Position Analysis

Assets

0.17 B
Current Assets
0.14 B
Total non-current assets
0.039 B

Total current liabilities
0.02 B
Total non-current liabilities
0.012 B

Cash Flow Statement

-0.021 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.021 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Aclaris Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-49 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-124 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-37 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is ACRS attractive for investment based on fundamental analysis?

ACRS stock rating is hidden. Aclaris Therapeutics is a hidden by Eyestock methodology.

Get ACRS Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-248

Gross Margin:

42

CFO / Debt ratio:

hidden

Current ratio:

5.144

Debt / Equity ratio:

ROE:

-49

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ACRS analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ACRS to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Aclaris Therapeutics Inc competitors

LL

LLY

Eli Lilly and Co

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs ...

Discover

NO

NOVO B.CO

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged i...

Discover

JN

JNJ

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in Ne...

Discover

Aclaris Therapeutics Inc dividends

ACRS dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ACRS stock

About the company Aclaris Therapeutics Inc

Market cap $B

0.095

Dividend yield

Shares outstanding

66.693 B

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 105 full-time employees. The company went IPO on 2015-10-07. The firm is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The firm is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. The company is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

ACRS profile

  • Ticker

    ACRS

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    07 October 2015

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    105

  • City

    Wayne

  • Address

    640 Lee Rd Ste 200

  • Cusip

    00461U105